MAPT and Alzheimer disease: Previous literature26 suggests that ‘probable’ AD cases (defined as those with low CSF amyloid beta1-42 and elevated tau levels) and high-risk for AD individuals (defined as asymptomatic but with low CSF amyloid beta1-42) exhibit significantly lower lumbar CSF cfmtDNA than controls.